In the Medical News & Perspectives article entitled "FDA Weighs
Communicating Drug-Related Risk to Patients" published in the August 11, 1999,
issue of THE JOURNAL (1999;282:515), the words "troglitazone (Rezulin, used
for type 2 diabetes)" should be deleted. No written informed consent has been
recommended or advised in connection with the prescription of this drug.